Abstract
Members of the cell division cycle 25 (Cdc25) family of proteins are highly conserved dual specificity phosphatases, which play a fundamental role in transitions between cell cycle phases during normal cell division through the activation of CdK/cyclin complexes. Furthermore, they are important targets of checkpoints in cellular pathways in the response to DNA damage. Over the past few years, more information about the basic enzymology of the Cdc25 phosphatases has emerged, with the identification of three Cdc25 phosphatase isoforms (A, B, and C) in mammalians. In particular, the Cdc25 A and B phosphatases have oncogenic properties and are overexpressed singly in some types of cancers and together in others. Therefore, it is not surprising that the Cdc25s are interesting targets for the development of new anticancer therapeutic strategies. In this review, we examine the most important classes of reversible inhibitors that show specificity for the Cdc25 A and B phosphatases (both singly and together) and the recent advances in the design of new potent Cdc25 A and B inhibitors. Using computational methodologies, we also consider their plausible mechanisms of action.
Keywords: Cancer, dual-specificity phosphatases, Cdc25 inhibitors, cell cycle, antiproliferative agents, docking, molecular modelling
Current Medicinal Chemistry
Title: CDC25A and B Dual-Specificity Phosphatase Inhibitors: Potential Agents for Cancer Therapy
Volume: 16 Issue: 15
Author(s): Antonio Lavecchia, Carmen Di Giovanni and Ettore Novellino
Affiliation:
Keywords: Cancer, dual-specificity phosphatases, Cdc25 inhibitors, cell cycle, antiproliferative agents, docking, molecular modelling
Abstract: Members of the cell division cycle 25 (Cdc25) family of proteins are highly conserved dual specificity phosphatases, which play a fundamental role in transitions between cell cycle phases during normal cell division through the activation of CdK/cyclin complexes. Furthermore, they are important targets of checkpoints in cellular pathways in the response to DNA damage. Over the past few years, more information about the basic enzymology of the Cdc25 phosphatases has emerged, with the identification of three Cdc25 phosphatase isoforms (A, B, and C) in mammalians. In particular, the Cdc25 A and B phosphatases have oncogenic properties and are overexpressed singly in some types of cancers and together in others. Therefore, it is not surprising that the Cdc25s are interesting targets for the development of new anticancer therapeutic strategies. In this review, we examine the most important classes of reversible inhibitors that show specificity for the Cdc25 A and B phosphatases (both singly and together) and the recent advances in the design of new potent Cdc25 A and B inhibitors. Using computational methodologies, we also consider their plausible mechanisms of action.
Export Options
About this article
Cite this article as:
Lavecchia Antonio, Di Giovanni Carmen and Novellino Ettore, CDC25A and B Dual-Specificity Phosphatase Inhibitors: Potential Agents for Cancer Therapy, Current Medicinal Chemistry 2009; 16 (15) . https://dx.doi.org/10.2174/092986709788186084
DOI https://dx.doi.org/10.2174/092986709788186084 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Structure-Function Relationships of Complement Receptor Type 2 (CR2; CD21)
Current Protein & Peptide Science Emerging Molecular Functions of MicroRNA-9: Cancer Pathology and Therapeutic Implications
Anti-Cancer Agents in Medicinal Chemistry In Situ Modulation of Oxidative Stress: A Novel and Efficient Strategy to Kill Cancer Cells
Current Medicinal Chemistry Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry Safer Vectors for Gene Therapy of Primary Immunodeficiencies
Current Gene Therapy The MYC Oncogene as a Cancer Drug Target
Current Cancer Drug Targets A 1536-Well Fluorescence Polarization Assay to Screen for Modulators of the MUSASHI Family of RNA-Binding Proteins
Combinatorial Chemistry & High Throughput Screening Differential Involvement of Myosin II and VI in the Spontaneous and SDF- 1-induced Migration of Adult CD133+ Hematopoietic Stem/Progenitor Cells and Leukemic Cells
Current Cancer Therapy Reviews Crystal Structures and Cytotoxicity of Ortho-Xylene Linked Bis-benzimidazolium Salts
Medicinal Chemistry Anti-Tumor Activity of Non-Nucleosidic Reverse Transcriptase Inhibitors
Current Pharmaceutical Design Neuroimaging of Non-Accidental Injury
Current Pediatric Reviews Chemokine Receptors as Targets for Cancer Therapy
Current Pharmaceutical Design Chemotherapy and Cardiotoxicity in Hematologic Malignancies
Current Cancer Drug Targets Malignancy in Common Variable Immune Deficiency: Report of Two Rare Cases of Gastrointestinal Malignancy and a Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets miRNAs as Modulators of Cholesterol in Breast Cancer Stem Cells: An Approach to Overcome Drug Resistance in Cancer
Current Drug Targets Advances in Research of Schiff-Base Metal Complexes as Potent Antioxidants
Current Medicinal Chemistry Rhein Derivatives, A Promising Pivot?
Mini-Reviews in Medicinal Chemistry Alternative Splicing in Chronic Myeloid Leukemia (CML): A Novel Therapeutic Target?
Current Cancer Drug Targets A Novel Fusicoccin Derivative Preferentially Targets Hypoxic Tumor Cells and Inhibits Tumor Growth in Xenografts
Anti-Cancer Agents in Medicinal Chemistry Nucleosides, a Valuable Chemical Marker for Quality Control in Traditional Chinese Medicine Cordyceps
Recent Patents on Biotechnology